AlphAIAlphAI — Financial news for AI agents
investing.comOCT 152 min read$LEGN

H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales

H.C. Wainwright reiterated a Buy rating and $65 price target for Legend Biotech (LEGN) due to strong Carvykti sales. Q3 2026 sales reached $710M, exceeding expectations. Revenue estimates were raised for 2026 and 2027. The stock trades at $19.04, below the price target and fair value estimate.

Original reporting
investing.com
Published Oct 15, 2026, 11:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LEGN
Bullish
high confidence
Mentioned
$LEGN
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LEGNBullishMed
01

Why it matters

The upgrade and raised price target suggest a near‑term upside opportunity.

02

Market read

Analyst rating change provides a fresh catalyst for LEGN, potentially driving short‑term buying interest.

03

What to watch

Potential pricing pressure from competitors and reimbursement uncertainties.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst reiteration follows a quarterly sales beat for Legend Biotech's CAR‑T product Carvykti.

Company-level read

Ticker impact

$LEGNBullishHigh confidence
Context

H.C. Wainwright reiterated a Buy rating and $65 price target after reporting stronger-than-expected Q3 Carvykti sales of $710 million.

Expected impact

likely upward pressure as investors price in the higher target and sales beat.

Evidence & confidence

The rating change and sizable sales beat provide a clear catalyst for buying interest.

Market effects

Sector

Biotech sector may benefit from positive sales momentum in CAR‑T therapies.

Regional

U.S. biotech stocks could see modest gains.

Global

Limited to investors tracking biotech pipelines.

Counterpoint

What could challenge this read

The rating may be premature given ongoing profitability concerns and recent CEO departure.

Key entities

  • company
    Legend Biotech Corp.

    Biotech firm developing CAR‑T therapies.

  • analyst_firm
    H.C. Wainwright

    Equity research house that issued the rating.

Read at source← All news

Related articles

OCT 2
$LEGNHighAI 8/10

Did Five Year CARVYKTI Data Just Shift Legend Biotech's (LEGN) Investment Narrative?

Legend Biotech (LEGN) reported five-year data from the CARTITUDE-2 trial, showing 50% of relapsed or refractory multiple myeloma patients alive and progression-free without maintenance after a single CARVYKTI infusion. The results strengthen CARVYKTI's clinical staying power and potential treatment positioning. The company reported a net loss of $91.5 million on $1.27 billion revenue, with analysts projecting 19.0% yearly revenue growth and a shift to positive net income by 2029.

simplywall.st3 min
SEP 25
$LEGNMedAI 8/10

Legend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myeloma

Legend Biotech (LEGN) reported five-year data from CARTITUDE-2 showing 50% of patients with earlier-line multiple myeloma remained progression-free after a single CARVYKTI infusion. The study, presented at the 2026 IMS Annual Meeting, showed a 69.2% overall survival rate, reinforcing CARVYKTI's potential for durable remission. CARVYKTI is a BCMA-directed cell therapy developed in collaboration with Janssen Biotech.

quiverquant.com2 min
AUG 25
$LEGNHighAI 8/10

Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?

Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M, up from $255.1M, and net income of $33.2M, reversing a prior loss. H1 2026 revenue was $692.6M, with net loss reduced to $21.1M. The company projects $2.2B revenue and $464.7M earnings by 2029. Analysts highlight CARVYKTI's role in profitability and pipeline assets. Management changes and CARVYKTI's dominance remain key risks.

simplywall.st2 min
AUG 14
$LEGNMedAI 8/10

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657M (+50% YoY), with U.S. $472M (+32%) and ex-U.S. $185M (+128%). Total revenue was $387.5M (+52%), adjusted net income $63.1M ($0.16/share), and cash $965M. Q3 gross margin guidance was lower-50% range.

aol.com6 min